Alpha-cinnamide compounds and compositions as hdac8 inhibitors
US-2016264518-A1 · Sep 15, 2016 · US
Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
US11059775B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11059775-B2 |
| Application number | US-201716461630-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 20, 2017 |
| Priority date | Nov 18, 2016 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
First claim
Opening claim text (preview).
That which is claimed: 1. A compound selected from the group consistinq of: and stereoisomers and pharmaceutically acceptable salts thereof.
Assignees
Inventors
Classifications
Ethylene carbonate · CPC title
- C07C259/06Primary
having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
Vinylene carbonate; Substituted vinylene carbonates · CPC title
with oxygen atoms in positions 1 and 3, e.g. phthalimide · CPC title
having oxygen atoms of hydroxylamino groups etherified · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11059775B2 cover?
- Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
- Who is the assignee on this patent?
- Univ Johns Hopkins, Inst Of Organic Chemistry And Biochemistry As Cr V V I, Inst Of Organic Chemistry & Biochemistry
- What technology area does this patent fall under?
- Primary CPC classification C07C259/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).